Woodline Partners Adds $3M in Bristol-Myers Squibb Company ($BMY)
The fund added over 51,000 shares, raising its holdings by nearly 5% in the latest SEC filing.
Key Points
- Woodline Partners increased its stake in Bristol-Myers Squibb by 4.8%, adding 51,521 shares to hold a total of 1,120,638 shares valued at $65.6 million.
- Bristol-Myers Squibb, a major player in the healthcare sector, trades at $58.56 with a market cap of $117.5 billion and a forward P/E of 9.33.
- Insiders recently traded shares, and analysts from B of A Securities and Piper Sandler maintain 'buy' ratings with price targets of $67 and $75, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Woodline Partners has increased its stake in Bristol-Myers Squibb Company (NYSE: BMY) by 4.8%, according to its latest 13F filing with the SEC. The fund added 51,521 shares during the reporting period, bringing its total holdings to 1,120,638 shares. The value of this position is approximately $65.6 million.
What Changed in Woodline Partners' Bristol-Myers Squibb Position
Woodline Partners boosted its stake in Bristol-Myers Squibb by 4.8%, adding 51,521 shares to its portfolio. This brings its total holdings to 1,120,638 shares, reflecting a significant investment valued at about $65.6 million.
Other Institutional Activity in Bristol-Myers Squibb
Several other institutional investors also adjusted their positions in Bristol-Myers Squibb. BlackRock, Inc. reduced its holdings by 5,142,518 shares, now holding 171,682,888 shares valued at approximately $10.4 billion. Vanguard Capital Management LLC opened a new position with 132,320,240 shares, valued at roughly $8 billion. State Street Corp added 584,476 shares, bringing its total to 98,564,914 shares worth about $6 billion. JPMorgan Chase & Co increased its stake by 17,107,541 shares, now holding 92,475,194 shares valued at $5.5 billion. Meanwhile, Charles Schwab Investment Management Inc cut its position by 10,207,019 shares, ending with 61,115,373 shares valued at $3.7 billion.
Bristol-Myers Squibb Company Stock Down 12.0%
Shares of NYSE: BMY traded near $58.56 on Tuesday. Bristol-Myers Squibb, a major player in the healthcare sector, boasts a market cap of $117.5 billion. The stock has a P/E ratio of 16.11 and a forward P/E of 9.33, with a beta of 0.238. It has traded between a 52-week low of $42.52 and a high of $62.89. The company's 50-day moving average is $57.09, and the 200-day moving average is $53.80.
$BMY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
For its recent quarter, Bristol-Myers Squibb reported revenue of $48.48 billion, with a growth rate of 2.6%. The company achieved a net margin of 15.0% and a return on equity of 38.7%. Earnings per share came in at $3.57. The next earnings report is scheduled for July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
Analyst view held steady after the report.
-
EPS & revenue
EPS beat estimates by 10.4%. Revenue beat estimates by 4.3%.
-
Profit surprise
EBITDA missed by 13 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
- Analyst signal
-
Earnings quality
Gross margin up 4.7 points. Operating margin down 3.0 points. Positive free cash flow.
Earnings Call Summary
Bristol delivered a solid first quarter with revenue of 11.5 billion dollars, up 1 percent year over year, and earnings per share of 1.58 dollars, beating Wall Street by 10 percent. The growth portfolio grew 9 percent, led by strong performances from Eliquis at 4.1 billion dollars and Breyanzi up 53 percent. Management highlighted progress across pipeline programs including positive data for Pumitamig and upcoming late-year readouts for Factor XI inhibitor Milvexian and Cobenfy in Alzheimer's disease psychosis.
Guidance Bristol reaffirmed its 2026 financial targets and said the company is tracking toward the upper end of guidance. The management team noted strong momentum in the growth portfolio and multiple clinical readouts expected in the second half of the year, including Milvexian in atrial fibrillation and Cobenfy in Alzheimer's psychosis.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Dividend
Bristol-Myers Squibb pays an annual dividend of $2.52, yielding 4.38% at current prices. The dividend payout ratio stands at 70.03%.
Insider Buying and Selling at Bristol-Myers Squibb Company
Recent insider activity at Bristol-Myers Squibb included trades by Julia Haller and Wendy Short Bartie. On June 15, 2026, Julia Haller bought and sold 20,460 shares at an average price of $53.76. Wendy Short Bartie, EVP of Corporate Affairs, sold 8,040 shares on June 3, 2026, at an undisclosed price.
Analysts Set New Price Targets
Analysts have been active with their ratings on Bristol-Myers Squibb. On April 9, 2026, B of A Securities maintained a 'buy' rating with a $67 price target. Piper Sandler also maintained a 'buy' rating with a $75 target on February 23, 2026. The consensus among 25 analysts is a 'hold', with an average price target of $63.08.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey. It focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's portfolio includes treatments for cancer, cardiovascular diseases, and immune-related conditions. Led by CEO Dr. Christopher S. Boerner, Bristol-Myers Squibb employs about 32,500 people worldwide.
Bottom Line
Woodline Partners' decision to increase its stake in Bristol-Myers Squibb underscores the fund's confidence in the company's long-term prospects. Investors often monitor such filings to gauge institutional sentiment. It's important to remember that 13F filings are backward-looking and might not reflect current positions.
Get Bristol-Myers Squibb Company alerts
New 13F filings, insider trades, and analyst moves on $BMY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.